|
KMID : 0927720100110020130
|
|
Korean Clinical Diabetes
2010 Volume.11 No. 2 p.130 ~ p.136
|
|
|
Management of Dyslipidemia in Type 2 Diabetes Mellitus
|
|
Kim Suk-Kyeong
|
|
|
Abstract
|
|
|
|
Dyslipidemia commonly associated with type 2 diabetes includes elevated triglycerides, low levels of high-density lipoprotein (HDL) cholesterol, and preponderance of small dense low-density lipoprotein (LDL) particles, with LDL cholesterol generally being similar to that of non-diabetic patients. The cornerstone of treatment for diabetic dyslipidemia is therapeutic lifestyle change. In addition to these measures, recent clinical trials have demonstrated the benefits of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor (statins) therapy. Although drug therapy for dyslipidemia must be individualized, most people with diabetes mellitus are candidates for statin therapy and often need to be treated with multiple agents to achieve therapeutic goals.
|
|
|
KEYWORD
|
|
|
Cardiovascular disease, Dyslipidemia, Statin, Type 2 DM
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|